Consistent with our findings, Yang et al. reported that patients receiving the AAP drug who carried the SREBF2 (rs2267443) A allele were at an increased risk for metabolic syndrome after controlling for a potentially confounding effect [12]. This evidence concerns the gene SREBF2 and metabolic syndrome.